View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 29, 2021

ARCA to advance Phase IIb Covid-19 therapy trial without modifications

The trial is analysing two doses of rNAPc2 versus heparin enrolling 160 Covid-19 patients with high D-dimer levels.

ARCA biopharma has reported that its Phase IIb ASPEN-COVID-19 clinical trial of the small recombinant protein, rNAPc2 (AB201), will progress without amendments.

The development comes after the Data and Safety Monitoring Committee (DSMC) conducted a pre-specified interim assessment and recommended completion of the trial without any modifications to the study design.

rNAPc2 is a selective tissue factor (TF) inhibitor and is claimed to possess anti-inflammatory, anti-coagulant and anti-viral properties. It is to be used as a treatment for hospitalised individuals with severe Covid-19,

The global multicentre, randomised Phase IIb trial is analysing two rNAPc2 dose schedules as against anti-coagulant, heparin, in nearly 160 Covid-infected subjects with high D-dimer levels.

The change in D-dimer level from baseline to day eight versus heparin is the primary goal of the trial.

Other goals of the trial include assessing safety, determining the appropriate dose regimen of rNAPc2 for a prospective Phase III trial and analysing various other clinical goals.

The company plans to conclude enrolment by the end of this year and report topline trial data in the first quarter of next year.

ARCA biopharma president and CEO Dr Michael Bristow said: “Clearing the final interim analysis with no recommended changes in the Phase IIb clinical trial design is an important step in a clinical trial and in the development of rNAPc2 for prevention of Covid-19-associated coagulopathy.

“We look forward to sharing the top-line trial results in the first quarter of next year and reviewing the findings with the FDA.”

In July, ARCA biopharma obtained approval from the regulatory agencies in Argentina and Brazil to initiate enrolment in Phase IIb trial of rNAPc2.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU